The SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS) will develop cellular-based and regenerative therapeutics and tools as new treatment strategies for key disease areas
The SingHealth Duke-NUS Academic Medical Centre (AMC) announced the launch of a research institute and disease centre that will advance regenerative medicine and introduce cellular therapies to improve patient care. Launched today at the inaugural SDCT-REMEDIS Cell Therapy Conference, the SingHealth Duke- NUS Regenerative Medicine Institute of Singapore (REMEDIS) and the SingHealth Duke- NUS Cell Therapy Centre (SDCT) will bring together multidisciplinary expertise and focus efforts in regenerative medicine research and its application for diagnostics and therapies to improve treatment outcomes for patients.
Regenerative medicine is a fast-growing area of medical research that looks at restoring, repairing or replacing damaged cells, tissue or organs in the body. It is particularly relevant for conditions such as cancer, heart disease, eye degeneration and neurological diseases. With a rapidly ageing population, where almost one in two of the population in Singapore will be at least 65 years of age by 20501, regenerative medicine is expected to have a significant impact in reducing the burden of disease here. One of the most promising approaches in regenerative medicine is cell therapy – the transplantation of healthy cells, such as stem cells, into a patient’s body to cure or treat disease. The joint launch of REMEDIS and SDCT will allow the seamless transfer of knowledge and outcomes for cellular regeneration, with a common goal towards disease management.
REMEDIS will harness the potential of regenerating diseased cells, tissue and even organs to develop research, regenerative therapies and tools to tackle age-related diseases and chronic conditions. The focus will be on seven disease areas: musculoskeletal diseases, bone marrow disorders, blood disorders, cardiovascular diseases, acute and chronic wound healing, neuro-sensory diseases and eye diseases. SDCT will bridge the gap by taking these cellular and gene regenerative therapies and tools into clinical trials and translate them into clinical applications that can benefit patients
Professor Ivy Ng, Group CEO, SingHealth said, “Many diseases do not yet have a cure, and often, the damage to the body from these conditions cannot be reversed. Regenerative medicine has been developing at an exponential rate globally, with more than 1,100 clinical trials worldwide currently showing promising results. The establishment of REMEDIS and SDCT will give us the opportunity to harness this cutting-edge science to develop novel clinical applications that will offer better health and overall quality of life.”
Professor Thomas Coffman, Dean, Duke-NUS Medical School (Duke-NUS), said, “The fields of cell therapy and regenerative medicine are game-changers, with the potential to improve the lives of millions of people who are suffering from chronic diseases or disorders related to ageing, and bring hope to those waiting on long organ transplant lists. With the establishment of REMEDIS and SDCT, we are combining the clinical expertise of SingHealth with Duke-NUS’ scientific firepower to drive impactful translational research that will lead to safe and effective new treatments that can be produced on a large scale.”
Ramping-up research in regenerative cell therapy
With support from the National Research Foundation (NRF), Singapore, REMEDIS will start off with a research study led by clinician-scientists from the SingHealth Duke-NUS AMC to develop cellular therapy products for three disease areas – age-related macular degeneration, ischemic cardiomyopathy and blood cancers. Due to the limitations of existing therapies, the research team is working toward safe and effective treatments for patients affected by these conditions.
For example, the current treatment for patients with blood cancers is chemotherapy or haematopoietic stem cell transplants. However, these treatment methods can lead to a low concentration of white blood cells or blood platelets in the body, which can be life- threatening. To address this, the team has identified a new way to generate mega doses of high-quality haematopoietic stem and progenitor cells in patients, which could expedite the recovery process.
Professor William Hwang, Head of SDCT, Co-director of REMEDIS, Medical Director of the National Cancer Centre of Singapore (NCCS) and principal investigator of the study said, “Using the latest advancements in cellular and regenerative medicine, we are developing strategies to regenerate and transplant bone marrow, cardiac muscles and retina cells and hope to improve treatment outcomes for these debilitating conditions. Once we have developed the cellular therapy products, we will study their safety and efficacy through clinical trials in SDCT’s network. Our first study is one will that will fully exploit the bench to bedside pipeline that we intended with the establishment of REMEDIS and SDCT.”
Director of REMEDIS, Principal Lead (Regenerative Medicine) of SDCT and Deputy Director (Research), NCCS, Prof Teh Bin Tean, shared, “The possibilities for application of cellular and regenerative medicine are limitless and REMEDIS and SDCT will continue to study new areas to improve health. Areas we will explore in the future include wound healing, trauma and chronic disease management.”
The inaugural SDCT-REMEDIS Cell Therapy Conference
The SDCT-REMEDIS Cell Therapy Conference, held from 21 to 22 May 2021, will showcase a rich line-up of leaders in cell-based immunotherapy and regenerative medicine who will share recent developments in their fields to improve patient diagnostics, therapeutics and care outcomes. Presenters include clinicians, scientists, collaborators from healthcare institutions, academia, industry and regulatory bodies who will provide valuable insight in their areas of expertise.
Subscribe to our mailing list to get the updates to your email inbox...